The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden
Open accessAbstract
Aims/hypothesis The aim of the present study was to estimate the prevalence and healthcare costs of diabetic retinopathy (DR).Methods This population-based study included all residents (n = 251,386) in the catchment area of the eye clinic of Linköping University Hospital, Sweden. Among patients with diabetes (n = 12,026), those with and without DR were identified through register data from both the Care Data Warehouse in Ostergötland, an administrative healthcare register, and the Swedish National Diabetes Register. Healthcare cost data were elicited by record linkage of these two registers to data for the year 2008 in the Cost Per Patient Database developed by Ostergötland County Council.Results The prevalence of any DR was 41.8% (95% CI 38.9-44.6) for patients with type 1 diabetes and 27.9% (27.1-28.7) for patients with type 2 diabetes. Sight-threatening DR was present in 12.1% (10.2-14.0) and 5.0% (4.6-5.4) of the type 1 and type 2 diabetes populations respectively. The annual average healthcare cost of any DR was euro72 (euro53-91). Stratified into background retinopathy, proliferative DR, maculopathy, and the last two conditions combined, the costs were euro26 (euro10-42), euro257 (euro155-359), euro216 (euro113-318) and euro433 (euro232-635) respectively. The annual cost for DR was euro106,000 per 100,000 inhabitants.Conclusions This study presents new information on the prevalence and costs of DR. Approximately one-third of patients with diabetes have some form of DR. Average healthcare costs increase considerably with the severity of DR, which suggests that preventing progression of DR may lower healthcare costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Of note, eight studies [47–53, 59] did not distinguish between costs of different conditions, further hindering the interpretation.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [52]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Costs associated with DMO were described in six studies for Spain (n = 2) [55, 57], Hungary [54], Italy [56], Sweden [52] and the UK [58].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Annual direct medical costs ranged from $45 to $613 in NPDR patients and from $441 to $3,031 in PDR patients (Fig. 5 and Supplementary Table 6), suggesting direct medical costs associated with PDR were about 5.8 times higher than those associated with NPDR.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Annual direct medical costs ranged from $45 to $613 in NPDR patients and from $441 to $3,031 in PDR patients (Fig. 5 and Supplementary Table 6), suggesting direct medical costs associated with PDR were about 5.8 times higher than those associated with NPDR.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the four studies reporting direct medical costs at the patient level, estimates ranged from $370 to $14,642 per annum [52, 54, 55, 57] (Fig. 6 and Supplementary Table 7).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [52]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Costs pertaining to DR and its complications (including DMO) were combined in three studies [50, 51, 53], whereas costs in patients affected by both DR and DMO simultaneously were reported in two studies [52, 53] (Supplementary Tables 3 and 8).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As for studies examining costs in patients affected by both DR and DMO [52, 53], direct medical costs ranged from $742 to $2,955 per patient per annum.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [52]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three studies, in Germany [53], Hungary [54] and Sweden [52], estimated costs associated with NPDR and PDR (Fig. 5 and Supplementary Table 6).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [52]
The cited source says what the claim attributes to it.
In the citing paper
“Nine articles [50–58] considered costs associated with DR and its associated complications (i.e. DMO).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Amos, A., Mccarty, D. J., & Zimmet, P. (1997) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199712)14:5+ · Cited by 2,247
The Wisconsin Epidemiologic Study of Diabetic Retinopathy
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,909
The Wisconsin Epidemiologic Study of Diabetic Retinopathy
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,482
The Wisconsin Epidemiologic Study of Diabetic Retinopathy
Klein, R., Klein, R., Moss, S. E., Davis, M. D., & DeMets, D. L. (1987) · Ophthalmology · doi:10.1016/s0161-6420(87)33525-0 · Cited by 1,247
The Prevalence of Diabetic Retinopathy Among Adults in the United States
Kempen, J. H., O'Colmain, B. J., Leske, M. C., Sm, H., Klein, R., Moss, S. E., Taylor, H. R., & Hamman, R. F. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.552 · Cited by 1,168
The Economic Burden of Major Adult Visual Disorders in the United States
Rein, D. B. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.12.1754 · Cited by 639
Epidemiology of diabetic retinopathy and macular oedema: A systematic review
Williams, R., Airey, M., Baxter, H., Forrester, J., Kennedy-Martin, T., & Girach, A. (2004) · Eye · doi:10.1038/sj.eye.6701476 · Cited by 472
United Kingdom Prospective Diabetes Study, 30
KOHNER, E. M. (1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.3.297 · Cited by 471
The National Diabetes Register in Sweden
Guðbjörnsdóttir, S., Cederholm, J., Nilsson, P. M., & Eliasson, B. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1270 · Cited by 264
Cited by
Sorted by citations
The progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A. J., Gardiner, T. A., Lyons, T. J., Hammes, H., Simó, R., et al. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,202
Ting, D. S. W., Cheung, G. C. M., & Wong, T. Y. (2016) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.12696 · Cited by 1,066
The worldwide epidemic of diabetic retinopathy
Congdon, N. G., Zheng, Y., & He, M. (2012) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.100542 · Cited by 633
Neurodegeneration in diabetic retinopathy: does it really matter?
Simó, R., Stitt, A. W., & Gardner, T. W. (2018) · Diabetologia · doi:10.1007/s00125-018-4692-1 · Cited by 617
Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives
Simó, R., & Hernández, C. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.09.005 · Cited by 506
Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries
Ruta, L. M., Magliano, D. J., LeMesurier, R., Taylor, H. R., Zimmet, P. Z., & Shaw, J. E. (2013) · Diabetic Medicine · doi:10.1111/dme.12119 · Cited by 311
Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence
Simó, R., & Hernández, C. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.003 · Cited by 247
Diabetic Retinopathy in the Context of Patients with Diabetes
Simó‐Servat, O., Hernández, C., & Simó, R. (2019) · Ophthalmic Research · doi:10.1159/000499541 · Cited by 249
Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies
Rodríguez, M. L., Pérez, S., Mena, S., Desco, C., & Ortega, Á. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4940825 · Cited by 234
Local and Systemic Inflammatory Biomarkers of Diabetic Retinopathy: An Integrative Approach
Vujosevic, S., & Simó, R. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-21769 · Cited by 166
Phenotypes and biomarkers of diabetic retinopathy
Cunha-Vaz, J. G., Ribeiro, L., & Lobo, C. L. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.03.003 · Cited by 164
Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications
Simó, R., & Hernández, C. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-302005 · Cited by 152
Sivaprasad, S., Gupta, B., Gulliford, M. C., Dodhia, H., Mohamed, M. D., Nagi, D. K., & Evans, J. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032182 · Cited by 142
Liu, Y., Yang, J., Tao, L., Lv, H., Jiang, X., Zhang, M., & Li, X. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016280 · Cited by 122
Al‐Rubeaan, K., Abu El‐Asrar, A. M., Youssef, A. M., Subhani, S. N., Ahmad, N. A., Al‐Sharqawi, A. H., Alguwaihes, A., Alotaibi, M. S., Al‐Ghamdi, A., & Ibrahim, H. M. (2015) · Acta Ophthalmologica · doi:10.1111/aos.12532 · Cited by 108
Obstructive Sleep Apnea and Retinopathy in Patients with Type 2 Diabetes. A Longitudinal Study
Altaf, Q. A., Dodson, P. M., Ali, A., Raymond, N. T., Wharton, H., Fellows, H., Hampshire-Bancroft, R., Shah, M., Shepherd, E., Miah, J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0175oc · Cited by 105
Zhivov, A., Winter, K., Hovakimyan, M., Peschel, S., Harder, V., Schober, H., Kundt, G., Baltrusch, S., Guthoff, R. F., & Stachs, O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052157 · Cited by 102
Fenofibrate – A Potential Systemic Treatment for Diabetic Retinopathy?
Wong, T. Y., Simó, R., & Mitchell, P. L. R. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.013 · Cited by 100
Interventions to increase attendance for diabetic retinopathy screening
Lawrenson, J. G., Graham-Rowe, E., Lorencatto, F., Burr, J. M., Bunce, C., Francis, J., Aluko, P., Rice, S. J. C., Vale, L. D., Pető, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012054.pub2 · Cited by 94
Usefulness of the Vitreous Fluid Analysis in the Translational Research of Diabetic Retinopathy
Simó‐Servat, O., Hernández, C., & Simó, R. (2012) · Mediators of Inflammation · doi:10.1155/2012/872978 · Cited by 94
Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology
Simó‐Servat, O., Simó, R., & Hernández, C. (2016) · Journal of Diabetes Research · doi:10.1155/2016/5263798 · Cited by 87
GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Simó, R., & Hernández, C. (2017) · Diabetes · doi:10.2337/db16-1364 · Cited by 86
Meng, W., Shah, K. P., Pollack, S. J., Toppila, I., Hébert, H. L., McCarthy, M. I., Groop, L., Ahlqvist, E., Lyssenko, V., Agardh, E., et al. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13769 · Cited by 79
Neuroprotection in Diabetic Retinopathy
Hernández, C., & Simó, R. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0284-5 · Cited by 68
Societal costs of non-cardiac chest pain compared with ischemic heart disease - a longitudinal study
Mourad, G., Alwin, J., Strömberg, A., & Jaarsma, T. (2013) · BMC Health Services Research · doi:10.1186/1472-6963-13-403 · Cited by 68
Song, S., Yu, X., Zhang, P., & Dai, H. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107641 · Cited by 65
Hashemi, H., Rezvan, F., Pakzad, R., Ansaripour, A., Heydarian, S., Yekta, A., Ostadimoghaddam, H., Pakbin, M., & Khabazkhoob, M. (2019) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1962920 · Cited by 65
Ponto, K. A., Koenig, J., Pető, T., Lamparter, J., Raum, P., Wild, P. S., Lackner, K. J., Pfeiffer, N., & Mirshahi, A. (2016) · Diabetologia · doi:10.1007/s00125-016-4013-5 · Cited by 55
Direct medical cost associated with diabetic retinopathy severity in type 2 diabetes in Singapore
Zhang, X., Low, S. K., Neelam, K., Wang, J., Ang, K., Yeo, D., Yip, C. C., Subramaniam, T., Sum, C. F., & Lim, S. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180949 · Cited by 47
Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema
Boscia, F. (2010) · Drugs · doi:10.2165/11538130-000000000-00000 · Cited by 45
Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms
Hernández, C., Simó-Servat, A., Bogdanov, P. M., & Simó, R. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0648-4 · Cited by 42
Diabetic retinopathy in type 1 diabetes patients in Western Norway
Jansson, R. W., Hufthammer, K. O., & Krohn, J. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13654 · Cited by 43
Hansen, M. J. B., Henriksen, J. E., Grauslund, J., & Pető, T. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13449 · Cited by 37
Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives
Hernández, C., Simó‐Servat, O., & Simó, R. (2014) · Endocrine · doi:10.1007/s12020-014-0232-z · Cited by 36
Fenofibrate for diabetic retinopathy
Yamamoto‐Kataoka, S., Lois, N., Kawano, S., Kataoka, Y., Inoue, K., & Watanabe, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013318.pub2 · Cited by 36
Cost of diabetic eye, renal and foot complications: a methodological review
Schirr-Bonnans, S., Costa, N., Derumeaux-Burel, H., Bos, J., Lepage, B., Garnault, V., Martini, J., Hanaire, H. P., Turnin, M., & Molinier, L. (2016) · The European Journal of Health Economics · doi:10.1007/s10198-016-0773-6 · Cited by 36
Matuszewski, W., Baranowska-Jurkun, A., Stefanowicz-Rutkowska, M. M., Modzelewski, R., Pieczyński, J., & Bandurska-Stankiewicz, E. M. (2020) · Medicina · doi:10.3390/medicina56040164 · Cited by 35
El‐Bab, M. F., Zaki, N. S., Mojaddidi, M. A., Albarry, M. A., & El-Beshbishy, H. A. (2013) · International Journal of General Medicine · doi:10.2147/ijgm.s40665 · Cited by 35
Pereira‐Figueiredo, D., Nascimento, A., Cunha-Rodrigues, M. C., Brito, R., & Calaza, K. D. C. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01077-4 · Cited by 35
Benhamza, M., Dahlui, M., & Said, M. A. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03665-6 · Cited by 32
Automated diabetic retinopathy screening for primary care settings using deep learning
Bhuiyan, A., Govindaiah, A., Deobhakta, A. A., Hossain, M., Rosen, R. B., & Smith, T. (2021) · Intelligence-Based Medicine · doi:10.1016/j.ibmed.2021.100045 · Cited by 34
Pugliese, G., Solini, A., Zoppini, G., Fondelli, C., Zerbini, G., Vedovato, M., Cavalot, F. L., Lamacchia, O., Buzzetti, R., Morano, S., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.006 · Cited by 30
Li, H., Li, G., Li, N., Liu, C., Yuan, Z., Gao, Q., Hao, S., Fan, S., & Yang, J. (2023) · PLOS ONE · doi:10.1371/journal.pone.0291390 · Cited by 27
Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review
Simó, R., Ballarini, S., Cunha-Vaz, J. G., Ji, L., Haller, H. G., Zimmet, P., & Wong, T. Y. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150520095923 · Cited by 26
Santonocito, M., Zappulla, C., Viola, S., Rosa, L. R. L., Solfato, E., Abbate, I., Tarallo, V., Apicella, I., Platania, C. B. M., Maugeri, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094404 · Cited by 25
Muc, R., Saracen, A., & Grabska‐Liberek, I. (2018) · Open Medicine · doi:10.1515/med-2018-0008 · Cited by 25
Topical treatment of diabetic retinopathy: a systematic review
Thagaard, M. S., Vergmann, A. S., & Grauslund, J. (2021) · Acta Ophthalmologica · doi:10.1111/aos.14912 · Cited by 24
Molecular Implications of the PPARs in the Diabetic Eye
Ciudin, A., Hernández, C., & Simó, R. (2013) · PPAR Research · doi:10.1155/2013/686525 · Cited by 24
Hautala, N. M., Hannula, V., Palosaari, T., Ebeling, T., & Falck, A. A. K. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12426 · Cited by 26
First nation-wide study of diabetic retinopathy in Poland in the years 2013–2017
Kozioł, M., Nowak, M. S., Udziela, M., Piątkiewicz, P., Grabska‐Liberek, I., & Szaflik, J. P. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01540-6 · Cited by 23
Societal cost of cancer in Norway –Results of taking a broader cost perspective
Bugge, C., Sæther, E. M., Brustugun, O. T., & Kristiansen, I. S. (2021) · Health Policy · doi:10.1016/j.healthpol.2021.05.008 · Cited by 22
Lv, Y., Zhai, C., Sun, G., & He, Y. (2024) · Journal of Biological Engineering · doi:10.1186/s13036-024-00414-7 · Cited by 22
Ma, M., Xu, Y., Xiong, S., Zhang, J., Gu, Q., Ke, B., & Xu, X. (2018) · Eye · doi:10.1038/s41433-018-0110-7 · Cited by 22
Association of lactate dehydrogenase and diabetic retinopathy in US adults with diabetes mellitus
Yang, P. C., Xu, W., Liu, L., & Yang, G. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13476 · Cited by 21
Effect of self-managed lifestyle treatment on glycemic control in patients with type 2 diabetes
Dwibedi, C. K., Mellergård, E., Gyllensten, A. C., Nilsson, K., Axelsson, A. S., Bäckman, M., Sahlgren, M., Friend, S. H., Persson, S., Franzén, S., et al. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00606-9 · Cited by 26
Cost consequences of point-of-care troponin T testing in a Swedish primary health care setting
Nilsson, S., Andersson, A., Janzon, M., Karlsson, J., & Levin, L. (2014) · Scandinavian Journal of Primary Health Care · doi:10.3109/02813432.2014.984901 · Cited by 21
Self-citationDiabetic Retinopathy Screening and Registration in Europe—Narrative Review
Hristova, E. G., Koseva, D., Zlatarova, Z. I., & Dokova, K. G. (2021) · Healthcare · doi:10.3390/healthcare9060745 · Cited by 21
Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?
Simó, R., Simó‐Servat, O., & Hernández, C. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0599-0 · Cited by 18
Adelborg, K., Szentkúti, P., Henriksen, J. E., Thomsen, R. W., Pedersen, L. H., Sundbøll, J., Sørensen, H. T., Nielsen, O. H., & Beck‐Nielsen, H. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-035492 · Cited by 18
Diabetic Retinopathy Environment-Wide Association Study (EWAS) in NHANES 2005–2008
Blighe, K., Gurudas, S., Lee, Y., & Sivaprasad, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113643 · Cited by 18
Association between serum heavy metal levels and diabetic retinopathy in NHANES 2011–2020
Zhang, Y., Liu, X., Zhang, X., Li, L., Li, Q., Geng, H., Shi, L., Wang, B., Qiu, Q., Yu, T., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51749-6 · Cited by 17
Patient-Centered Economic Burden of Diabetic Macular Edema: Retrospective Cohort Study
Choi, K., Park, S. J., Yoon, H., Choi, S., Mun, Y., Kim, S., Yoo, S., Woo, S. J., Park, K. H., Na, J., et al. (2024) · JMIR Public Health and Surveillance · doi:10.2196/56741 · Cited by 16
Chen, Y., & Chen, Y.-J. (2022) · Nutrients · doi:10.3390/nu14051086 · Cited by 16
Determinants of diabetic retinopathy in Tikur Anbessa Hospital, Ethiopia: a case–control study
Seid, K., Tesfaye, T., Gizaw, A. B., & Mohammed, H. (2021) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-021-00128-5 · Cited by 15
Incidence of Diabetic Retinopathy in Individuals with Type 2 Diabetes: A Study Using Real-World Data
Hernández-Teixidó, C., Barrot, J., Miravet-Jiménez, S., Fernández‐Camins, B., Mauricio, D., Romero‐Aroca, P., Vlacho, B., & Franch‐Nadal, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237083 · Cited by 14
Ondrejkova, M., Jackuliak, P., Martinka, E., Mokáň, M., Foley, J. E., Fabkova, J., Gecik, K., Tvrda, I., Helbich, M., Gajdošová, M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223788 · Cited by 15
Hu, Z., Xie, C., Yang, M., Fu, X., Gao, H., Liu, Y., & Xie, H. (2020) · Phytotherapy Research · doi:10.1002/ptr.6844 · Cited by 14
Comparative analysis of delivery of primary eye care in three European countries
Jahn, R., Thomas, D., Weegen, L., Wasem, J., & Walendzik, A. (2011) · Das Gesundheitswesen · doi:10.1055/s-0031-1283496 · Cited by 12
Interventions to increase attendance for diabetic retinopathy screening
Lawrenson, J. G., Graham-Rowe, E., Lorencatto, F., Presseau, J., Burr, J., Ivers, N., Quartilho, A., Bunce, C., Francis, J. J., Grimshaw, J. M., et al. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012054 · Cited by 10
Jiang, L., Hu, X., & Cai, L. (2022) · Molecules · doi:10.3390/molecules27113472 · Cited by 10
Intravitreal bromfenac liposomal suspension (100 μg / 0.1 ml). A safety study in rabbit eyes
Sánchez-Santos, I., García‐Sánchez, G. A., González-Salinas, R., Linares-Alba, M. A., Rodríguez-Reyes, A. A., García‐Santisteban, R., Tirado, V., Piñamora, E. C. H., García-Arzate, D., Morales-Cantón, V., et al. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108020 · Cited by 10
Surowiec, P., Matejko, B., Kopka, M., Filemonowicz-Skoczek, A., Klupa, T., Cyganek, K., Romanowska‐Dixon, B., & Malecki, M. T. (2021) · Endocrine · doi:10.1007/s12020-021-02871-2 · Cited by 10
Alamri, A., Al-Jahash, N. A. S., Alsultan, M. S. H., AlQahtani, S. S. A., Saeed, Y. A. A., & Alhamlan, R. A. O. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_86_21 · Cited by 10
JENDLE, J. H., Ericsson, Å., Hunt, B., Valentine, W. J., & Pollock, R. F. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0344-6 · Cited by 10
Alsbirk, K. E., Seland, J. H., & Aßmus, J. (2021) · Acta Ophthalmologica · doi:10.1111/aos.14977 · Cited by 9
Murchison, A. P., Haller, J. A., Mayro, E. L., Hark, L. A., Gower, E. W., Huisingh, C., Rhodes, L. A., Friedman, D. S., Lee, D. J., Lam, B. L., et al. (2017) · Current Eye Research · doi:10.1080/02713683.2017.1297463 · Cited by 10
Shan, Y., Xu, Y., Ye, L., Lin, X., Chen, Y., Qi, M., & Ye, J. (2021) · Endocrine · doi:10.1007/s12020-021-02692-3 · Cited by 8
Jia, J., Liu, B., Wang, X., Ji, F., Wen, F., Xu, H., & Ding, T. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1453436 · Cited by 6
Granstam, E., Rosenblad, A., Raghib, A. M., Granström, T., Eriksson, J. W., Olinder, A. L., & Leksell, J. K. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14290 · Cited by 6
Fenofibrate for diabetic retinopathy
Inoue, K., Yamamoto‐Kataoka, S., Kawano, S., Furukawa, T. A., Lois, N., & Watanabe, N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013318 · Cited by 6
Effects of qiming granule for diabetic macular edema
Hu, Z., Yang, M., Xie, C., Gao, H., Fu, X., Xie, H., & Liu, Y. (2019) · Medicine · doi:10.1097/md.0000000000017496 · Cited by 5
Yakob, T., Abraham, A., Yakob, B., & Jaldo, M. M. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-090916 · Cited by 5
Noor, A. K. C. M., Tai, E. L. M., Kueh, Y. C., Siti‐Azrin, A. H., Noordin, Z., & Shatriah, I. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17010310 · Cited by 5
Šín, M., Ženíšková, R., Slíva, M., Dvořák, K., Vaľková, J., Bayer, J., Karasová, B., Tesař, J., Fillová, D., & Prázný, M. (2025) · Clinical ophthalmology · doi:10.2147/opth.s511233 · Cited by 4
Roser, P., Grohmann, C., Aberle, J., Spitzer, M. S., & Kromer, R. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1484-9678 · Cited by 3
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
Nenkova, I., Lilova, Y., Oscar, A. H., Levi, A., Kamusheva, M., & Petrova, G. I. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70270 · Cited by 2
Saravanan, K., Elavarasi, S., Revathi, G., Karuppannan, P., Ashokkumar, M., & Kumar, K. J. S. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.120996 · Cited by 2
Remote Eye Triage: Health Economic Perspectives on Resource Prioritization
van der Zee, C., Wisse, R. P. L., Imhof, S. M., & van der Meulen, M. P. (2025) · Health Services Insights · doi:10.1177/11786329251347684 · Cited by 1
Borjan, I., Pleština-Borjan, I., Znaor, L., Pavić, M., Josifova, T., Marković, I., Petrovski, B. É., & Petrovski, G. (2025) · Medicina · doi:10.3390/medicina61122168 · Cited by 1
Christensen, M. H., Vinter, C. A., Petersen, M. H., Andersen, M. S., Grauslund, J., & Jensen, D. M. (2026) · Diabetes Care · doi:10.2337/dc25-3074 · Cited by 1
Roser, P., Grohmann, C., Aberle, J., Spitzer, M. S., & Kromer, R. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1521-7645 · Cited by 1
Ziemssen, F., & Agostini, H. T. (2016) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-319-24097-8_6 · Cited by 1
Alshehri, A. M., Almutairi, M. N., Alqahtani, M. M., & Al-Fakhri, A. S. (2025) · International Journal of Retina and Vitreous · doi:10.1186/s40942-025-00747-5 · Cited by 1
Fenofibrato en la retinopatía diabética: de los resultados clínicos al mecanismo de acción
Simó, R. (2012) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(12)70011-6 · Cited by 1
Mourad, G. (2015) · Linköping University medical dissertations · doi:10.3384/diss.diva-122592 · Cited by 1
Mabaso, R. G. (2013) · Unisa Institutional Repository (University of South Africa) · Cited by 1
Willmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
“a. Costs associated with non-proliferative diabetic (NPDR) and proliferative diabetic retinopathy (PDR) Three studies, in Germany [53], Hungary [54] and Sweden [52], estimated costs associated with NPDR and PDR (Fig.”
InfluentialKontinuerlig subkutan glukosmätning vid diabetes
Johansson, U., Hanås, R., Olsson, P.-O., Olinder, A. L., Persson, M., Werkö, S. S., Jacobson, S., Heintz, E., Akcan, D., Granath, A., et al. (2013)
Self-citationVisual impairment, blindness and retinopathy in older Icelanders
Gunnlaugsdóttir, E. (2013) · Skemman
Cone Photoreceptor Structure and Function in Adolescents and Young Adults with Type 1 Diabetes
Finkelberg, L. (2014) · TSpace (University of Toronto)
Metadata
- Authors
- Heintz, E., Wiréhn, A.-B., Peebo, B. B., Rosenqvist, U., & Levin, L.-Å.
- Affiliations
- Linköping University (SE)
- Ryhov Hospital Jönköping (SE)
- Lasarettet i Motala (SE)
- Corresponding author
- Heintz, E.
- Venue
- Diabetologia
- Published
- 2010-07-02
- Volume
- 53
- Issue
- 10
- Pages
- 2147-2154
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1996708310
- Cited by
- 107
- References
- 27
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 7 · 2023: 4 · 2022: 4 · 2021: 15 · 2020: 8 · 2019: 7 · 2018: 6 · 2017: 9 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 9 · 2012: 8
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Länsstyrelsen Östergötland
- Linköpings Universitet
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, prevalence, health care costs, type 1 diabetes, type 2 diabetes, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic maculopathy, background retinopathy, retinopathy severity, cost per patient, Östergötland
- MeSH terms
- Cross-Sectional Studies, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Female, Humans, Male, Registries, Sweden, Prevalence, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
